Ziprasidone hydrochloride (Synonyms: CP-88059 hydrochloride)

Ziprasidone (CP-88059) hydrochloride, an antipsychotic agent, is a combined 5-HT (serotonin) and dopamine receptor antagonist. Ziprasidone hydrochloride has high affinity for rat (K_i: 3.4 nM)/human (2.5 nM) 5-HT1A receptors, 5-HT2A (0.42 nM), and dopamine D2 receptors (4.8 nM). Ziprasidone hydrochloride is an inhibitor of norepinephrine reuptake^[1][2].

Ziprasidone is a 5-HT1A receptor agonist and an antagonist at 5-HT2A, 5-HT2C and 5-HT1B/1D receptors. Ziprasidone has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes^[1][2][3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ziprasidone (20 mg/kg; p.o.; daily for 7 weeks) gains significantly less weight, has a lower level of physical activity, showed a higher resting energy expenditure, and displays a greater capacity for thermogenesis when subjected to cold^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

449.40

C₂₁H₂₂Cl₂N₄OS

122883-93-6

ClC1=CC2=C(CC(N2)=O)C=C1CCN(CC3)CCN3C4=NSC5=C4C=CC=C5.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rollema H, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48(3):229-237.

  [2]. Schmidt AW, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425(3):197-201.

  [3]. Seeger TF, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275(1):101-113.

  [4]. Park S, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012;61(6):787-793.